SCHEDULE 13G
Amendment No. 0
Human Genome Sciences Incorporated
common stock
Cusip # 444903108
Cusip # 444903108
Item 1: Reporting Person - FMR Corp.
Item 4: Commonwealth of Massachusetts
Item 5: 100,100
Item 6: 0
Item 7: 1,965,107
Item 8: 0
Item 9: 2,205,717
Item 11: 9.585%
Item 12: HC
Cusip # 444903108
Item 1: Reporting Person - Edward C. Johnson 3d
Item 4: United States of America
Item 5: 0
Item 6: 0
Item 7: 2,205,717
Item 8: 0
Item 9: 2,205,717
Item 11: 9.585%
Item 12: IN
Cusip # 444903108
Item 1: Reporting Person - Abigail P. Johnson
Item 4: United States of America
Item 5: 0
Item 6: 0
Item 7: 2,205,717
Item 8: 0
Item 9: 2,205,717
Item 11: 9.585%
Item 12: IN
Cusip # 444903108
Item 1: Reporting Person - Fidelity International Limited
Item 4: Bermuda
Item 5: 240,610
Item 6: 0
Item 7: 240,610
Item 8: 0
Item 9: 2,205,717
Item 11: 9.585%
Item 12: HC
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(c)
Item 1(a). Name of Issuer:
Human Genome Sciences Incorporated
Item 1(b). Name of Issuer's Principal Executive Offices:
9410 Key West Avenue,
Rockville, MD 20850-3331
Item 2(a). Name of Person Filing:
FMR Corp.
Item 2(b). Address or Principal Business Office or, if None,
Residence:
82 Devonshire Street, Boston, Massachusetts 02109
Item 2(c). Citizenship:
Not applicable
Item 2(d). Title of Class of Securities:
common stock
Item 2(e). CUSIP Number:
444903108
Item 3. This statement is filed pursuant to Rule 13d-1(c).
Not applicable
Item 4. Ownership
(a) Amount Beneficially Owned: 2,205,717
(b) Percent of Class: 9.585%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 340,710
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition of:
2,205,717
(iv) shared power to dispose or to direct the disposition of:
0
Item 5. Ownership of Five Percent or Less of a Common Stock.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Various persons have the right to receive or the power to direct
the receipt of dividends from, or the proceeds from the sale of, the
common stock of Human Genome Sciences Incorporated. No one person's
interest in the common stock of Human Genome Sciences Incorporated is
more than five percent of the total outstanding common stock.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding Company.
See attached Exhibit(s) A, B, and C.
Item 8. Identification and Classification of Members of the Group.
Not Applicable. See attached Exhibit A.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction
having that purpose or effect.
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this Schedule 13G
in connection with FMR Corp.'s beneficial ownership of the common stock
of Human Genome Sciences Incorporated at September 10, 1999 is true,
complete and correct.
September 15, 1999
Date
Signature
Eric D. Roiter
Duly authorized under Power of Attorney
dated December 30, 1997, by and on behalf
of FMR Corp. and its direct and indirect
subsidiaries.
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(c)
Pursuant to the instructions in Item 7 of Schedule 13G, Fidelity
Management & Research Company ("Fidelity"), 82 Devonshire Street,
Boston, Massachusetts 02109, a wholly-owned subsidiary of FMR Corp. and
an investment adviser registered under Section 203 of the Investment
Advisers Act of 1940, is the beneficial owner of 1,814,407 shares or
7.884% of the common stock outstanding of Human Genome Sciences
Incorporated ("the Company") as a result of acting as investment
adviser to various investment companies (the "funds") registered under
Section 8 of the Investment Company Act of 1940. The number of shares
of common stock of Human Genome Sciences Incorporated owned by the
investment companies at September 10, 1999 included 32,567 shares of
common stock resulting from the assumed conversion of $1,700,000
principal amount of HUMAN GENOME 5.5% 7/01/06 144A (19.1571 shares of
common stock for each $1,000 principal amount of debenture).
Edward C. Johnson 3d, FMR Corp., through its control of Fidelity,
and the funds collectively each has sole power to dispose of the
1,814,407 shares owned by the Funds.
Neither FMR Corp. nor Edward C. Johnson 3d, Chairman of FMR
Corp., has the sole power to vote or direct the voting of the shares
owned directly by the funds, which power resides with the funds' Boards
of Trustees. Fidelity carries out the voting of the shares under
written guidelines established by the funds' Boards of Trustees.
Fidelity Management Trust Company, 82 Devonshire Street, Boston,
Massachusetts 02109, a wholly-owned subsidiary of FMR Corp. and a bank
as defined in Section 3(a)(6) of the Securities Exchange Act of 1934,
is the beneficial owner of 150,700 shares or 0.654% of the common stock
outstanding of the Company as a result of its serving as investment
manager of the institutional account(s).
Edward C. Johnson 3d and FMR Corp., through its control of
Fidelity Management Trust Company, each has sole dispositive power over
150,700 shares and sole power to vote or to direct the voting of
100,100 shares.
Members of the Edward C. Johnson 3d family are the predominant
owners of Class B shares of common stock of FMR Corp., representing
approximately 49% of the voting power of FMR Corp. Mr. Johnson 3d owns
12.0% and Abigail Johnson owns 24.5% of the aggregate outstanding
voting stock of FMR Corp. Mr. Johnson 3d is Chairman of FMR Corp. and
Abigail P. Johnson is a Director of FMR Corp. The Johnson family group
and all other Class B shareholders have entered into a shareholders'
voting agreement under which all Class B shares will be voted in
accordance with the majority vote of Class B shares. Accordingly,
through their ownership of voting common stock and the execution of the
shareholders' voting agreement, members of the Johnson family may be
deemed, under the Investment Company Act of 1940, to form a controlling
group with respect to FMR Corp.
Fidelity International Limited, Pembroke Hall, 42 Crowlane,
Hamilton, Bermuda, and various foreign-based subsidiaries provide
investment advisory and management services to a number of non-U.S.
investment companies and certain institutional investors. Fidelity
International Limited is the beneficial owner of 240,610 shares or
1.045% of the common stock outstanding of the Company. Additional
information with respect to the beneficial ownership of Fidelity
International Limited is shown on Exhibit B.
EXHIBIT to SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(c)
Pursuant to instructions in Item 7 of Schedule 13G, this Exhibit
has been prepared to identify Fidelity International Limited, Pembroke
Hall, 42 Crow Lane, Hamilton, Bermuda, a Bermudan joint stock company
incorporated for an unlimited duration by private act of the Bermuda
Legislature (FIL) and an investment adviser to various investment
companies (the "International Funds") and certain institutional
investors, as a beneficial owner of the 240,610 shares or 1.045% of the
common stock outstanding of Human Genome Sciences Incorporated.
Prior to June 30, 1980, FIL was a majority-owned subsidiary of
Fidelity Management & Research Company (Fidelity), a wholly-owned
subsidiary of FMR Corp. On that date, the shares of FIL held by
Fidelity were distributed, as a dividend, to the shareholders of FMR
Corp. FIL currently operates as an entity independent of FMR Corp. and
Fidelity. The International Funds and FIL's other clients, with the
exception of Fidelity and an affiliated company of Fidelity, are non-
U.S. entities.
A partnership controlled by Edward C. Johnson 3d and members of
his family owns shares of FIL voting stock with the right to cast
approximately 39.89% of the total votes which may be cast by all
holders of FIL voting stock. Mr. Johnson 3d is Chairman of FMR Corp.
and FIL. FMR Corp. and FIL are separate and independent corporate
entities, and their Boards of Directors are generally composed of
different individuals. Other than when one serves as a sub adviser to
the other, their investment decisions are made independently, and their
clients are generally different organizations.
FMR Corp. and FIL are of the view that they are not acting as a
"group" for purposes of Section 13(d) under the Securities Exchange Act
of 1934 (the "1934" Act) and that they are not otherwise required to
attribute to each other the "beneficial ownership" of securities
"beneficially owned" by the other corporation within the meaning of
Rule 13d-3 promulgated under the 1934 Act. Therefore, they are of the
view that the shares held by the other corporation need not be
aggregated for purposes of Section 13(d). However, FMR Corp. is making
this filing on a voluntary basis as if all of the shares are
beneficially owned by FMR Corp. and FIL on a joint basis.
FIL has sole dispositive power over 240,610 shares owned by the
International Funds. FIL has sole power to vote or direct the voting of
240,610 shares of common stock held by the International Funds as
reported above.
SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(c)
RULE 13d-1(f)(1) AGREEMENT
The undersigned persons, on September 15, 1999, agree and consent
to the joint filing on their behalf of this Schedule 13G in connection
with their beneficial ownership of the common stock of Human Genome
Sciences Incorporated at September 10, 1999.
FMR Corp.
By /s/Eric D. Roiter
Eric D. Roiter
Duly authorized under Power of Attorney
dated December 30, 1997, by and on behalf
of FMR Corp. and its direct and indirect
subsidiaries.
Edward C. Johnson 3d
By /s/Eric D. Roiter
Eric D. Roiter
Duly authorized under Power of Attorney
dated December 30, 1997, by and on behalf
of Edward C. Johnson 3d.
Abigail P. Johnson
By /s/Eric D. Roiter
Eric D. Roiter
Duly authorized under Power of Attorney
dated December 30, 1997, by and on behalf
of Abigail P. Johnson.
Fidelity Management & Research Company
By /s/Eric D. Roiter
Eric D. Roiter
V.P. and General Counsel
